Focused On-demand Library for AN1-type zinc finger protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86XD8

UPID:

ZFAN4_HUMAN

Alternative names:

AN1-type zinc finger and ubiquitin domain-containing protein-like 1

Alternative UPACC:

Q86XD8; A8K8V4; B2RAX2; Q5VVY5

Background:

AN1-type zinc finger protein 4, alternatively known as AN1-type zinc finger and ubiquitin domain-containing protein-like 1, plays a crucial role in cellular processes through its involvement in ubiquitin-mediated protein degradation pathways. Its unique structure, characterized by the presence of AN1-type zinc finger domains, suggests a specialized function in protein-protein interactions.

Therapeutic significance:

Understanding the role of AN1-type zinc finger protein 4 could open doors to potential therapeutic strategies. Its involvement in protein degradation pathways highlights its importance in maintaining cellular homeostasis and presents an opportunity for targeted drug discovery efforts.